TY - JOUR AU - Gridelli, Cesare AU - Losanno, Tania PY - 2016 TI - A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting JF - Journal of Thoracic Disease; Vol 8, No 11 (November 16, 2016): Journal of Thoracic Disease Y2 - 2016 KW - N2 - EGFR mutation-positive non-small cell lung cancer (NSCLC) is a well-defined molecular subtype of lung cancer. We already know data on frequency and characteristics of EGFR mutations among patients with NSCLC and their response to tyrosine kinase inhibitors (TKIs) (1). Actually these small molecules represent the standard first-line treatments for this setting of patients, while platinum-based doublet chemotherapy is the standard first-line treatment for patients with wild type EGFR NSCLC (2). UR - https://jtd.amegroups.org/article/view/10636